Abstract
The involvement of prostaglandin D2 (PGD2) in inflammatory diseases like allergy and asthma is well established, thus blocking the effect of this mediator represents a novel therapeutic approach for the treatment of such diseases. PGD2 is now known to act through two seven-transmembrane (7TM) receptors, DP (DP1) and CRTH2 (DP2), which are also activated by several endogenous metabolites from the arachidonic acid cascade, making the regulatory system highly complex. There has recently been a considerable effort aimed at developing antagonists of the PGD2 receptors for treatment of inflammatory conditions like asthma and rhinitis. Several potent DP antagonists are now known, and one of these is currently in clinical trials for treatment of asthma. CRTH2 has received much attention since its identification as the second high affinity PGD 2 receptor in 2001, and a number of potent and selective antagonists have recently become available. This review will briefly discuss the biological background and validation of DP and CRTH2 as targets for antiinflammatory drugs, and then highlight developments in medicinal chemistry which have appeared in journals and patent applications in the last few years, and which have brought us closer to therapeutic applications of PGD2 receptor antagonists in various indications.
Keywords: NSAIDs, inflammatory diseases, D Prostanoid Recepto, CRTH2 Agonists, Ramatroban, indomethacin
Current Topics in Medicinal Chemistry
Title: Targeting the Prostaglandin D2 Receptors DP and CRTH2 for Treatment of Inflammation
Volume: 6 Issue: 13
Author(s): Trond Ulven and Evi Kostenis
Affiliation:
Keywords: NSAIDs, inflammatory diseases, D Prostanoid Recepto, CRTH2 Agonists, Ramatroban, indomethacin
Abstract: The involvement of prostaglandin D2 (PGD2) in inflammatory diseases like allergy and asthma is well established, thus blocking the effect of this mediator represents a novel therapeutic approach for the treatment of such diseases. PGD2 is now known to act through two seven-transmembrane (7TM) receptors, DP (DP1) and CRTH2 (DP2), which are also activated by several endogenous metabolites from the arachidonic acid cascade, making the regulatory system highly complex. There has recently been a considerable effort aimed at developing antagonists of the PGD2 receptors for treatment of inflammatory conditions like asthma and rhinitis. Several potent DP antagonists are now known, and one of these is currently in clinical trials for treatment of asthma. CRTH2 has received much attention since its identification as the second high affinity PGD 2 receptor in 2001, and a number of potent and selective antagonists have recently become available. This review will briefly discuss the biological background and validation of DP and CRTH2 as targets for antiinflammatory drugs, and then highlight developments in medicinal chemistry which have appeared in journals and patent applications in the last few years, and which have brought us closer to therapeutic applications of PGD2 receptor antagonists in various indications.
Export Options
About this article
Cite this article as:
Ulven Trond and Kostenis Evi, Targeting the Prostaglandin D2 Receptors DP and CRTH2 for Treatment of Inflammation, Current Topics in Medicinal Chemistry 2006; 6 (13) . https://dx.doi.org/10.2174/15680266106061427
DOI https://dx.doi.org/10.2174/15680266106061427 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation Biomarkers in Psychiatry
Current Psychiatry Research and Reviews Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics An Overview on Natural Polysaccharides with Antioxidant Properties
Current Medicinal Chemistry Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences Biodegradable Hydrogel Bead of Casein and Modified Xanthan Gum for Controlled Delivery of Theophylline
Current Drug Therapy Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Preface
Current Drug Targets - Inflammation & Allergy Editorial: Rediscovering Drug Discovery
Combinatorial Chemistry & High Throughput Screening Glucocorticoids and their Effects on Bone and Joints in Rheumatoid Arthritis
Current Rheumatology Reviews Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Vaccine Safety Monitoring Systems in Developing Countries: An Example of the Vietnam Model
Current Drug Safety Proteome Analysis of Resting Human Neutrophils
Protein & Peptide Letters Pharmacological Potential of Tetrahydrofurano/Pyrano Quinoline and Benzo[b]furoindolyl Derivatives in Acute Inflammation, Pain and Oxidative Stress
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Preface (Hot Topic: Pulmonary Inflammation Guest Editor: Momtchilo Russo)
Current Drug Targets - Inflammation & Allergy Selected Recent Advances in the Synthesis of Bioactive Compounds Using Olefin Metathesis as a Key Step
Current Organic Chemistry Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Advances in Titanium-Catalyzed Synthesis of Chiral Sulfoxide Drugs
Mini-Reviews in Organic Chemistry NLRP3 Inflammasome Activation Leading to IL-1 – IL-17 Dependent Lung Inflammation and Fibrosis
Current Respiratory Medicine Reviews